English

Magenta Therapeutics, Inc.

EDGAR

DNTH Quarterly report (10-Q) · filed 2026-08-04

Annual consolidated revenue for 2025: about USD 2.036M, using the latest reported figures. The previous period, 2024, was about USD 6.235M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

284 thousand USD

2025 Q4 · USD

Exact inputs and evidence

Revenue: 2036000 USD Source
Revenue: 1752000 USD Source

Operating margin

-24,486.27%

2025 Q4 · %

Exact inputs and evidence

Operating Income: -177933000 USD Source
Operating Income: -108392000 USD Source
Revenue: 2036000 USD Source
Revenue: 1752000 USD Source

Operating cash flow

-47 million USD

2025 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -129060000 USD Source
Operating Cash Flow: -82077000 USD Source

Cash and cash equivalents: 111 million USD 2026-06-30 Source
Exact value

110549000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 54.8 million shares 2026-06-30 Source
Exact value

54798338 shares

Reported share-count change

70.31% · 22.6 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

32176482 shares · 2025-06-30· Source
54798338 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

2.04 million USD

2025-01-01 – 2025-12-31

Exact inputs and evidence

Revenue: 1163000 USD · 2025-01-01 – 2025-03-31 Source
Revenue: 193000 USD · 2025-04-01 – 2025-06-30 Source
Revenue: 396000 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 2036000 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 1752000 USD · 2025-01-01 – 2025-09-30 Source

Net income

-192 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -36765000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -162337000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -97905000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -40834000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -50215000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-155 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -82077000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -51522000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -129060000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -82077000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -28856000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -77837000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -28856000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

403 thousand USD

2022-07-01 – 2023-06-30

Exact inputs and evidence

Capital expenditure: 314000 USD · 2022-01-01 – 2022-09-30 Source
Capital expenditure: 156000 USD · 2022-01-01 – 2022-06-30 Source
Capital expenditure: 314000 USD · 2022-01-01 – 2022-12-31 Source
Capital expenditure: 314000 USD · 2022-01-01 – 2022-09-30 Source
Capital expenditure: 245000 USD · 2023-01-01 – 2023-03-31 Source
Capital expenditure: 245000 USD · 2023-01-01 – 2023-06-30 Source
Capital expenditure: 245000 USD · 2023-01-01 – 2023-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-04.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 7 of 11 periods available· newest 2025-12-31
Operating income: 10 of 11 periods available· newest 2025-12-31
Net income: 10 of 11 periods available· newest 2025-12-31
Operating cash flow: 10 of 11 periods available· newest 2025-12-31
Capital expenditure: 7 of 11 periods available· newest 2022-12-31
Total assets: 6 of 11 periods available· newest 2025-12-31
Total liabilities: 6 of 11 periods available· newest 2025-12-31
Current assets: 6 of 11 periods available· newest 2025-12-31
Current liabilities: 6 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 7 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 6 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-67.3%

Prior period

USD 6.24 million

2024-01-01 – 2024-12-31
Current period

USD 2.04 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

2036000 − 6235000 = -4199000 USD

6235000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
2036000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Magenta Therapeutics, Inc. · 2025-12-31 Magenta Therapeutics, Inc. (edgar:1690585) Year-over-year change in Revenue: -4199000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T14:33:14Z Snapshot: ec53128c25bf511416abc660a9fc93feb2bdc4739bc4672074c449d4cdcb5b7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1690585?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 2036000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm#2031180 Filing: 000169058526000006 Input fundies:Revenue: 6235000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm#2032799 Filing: 000169058526000006
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 77.37 million

Prior period

−USD 84.97 million

2024-01-01 – 2024-12-31
Current period

−USD 162.34 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-162337000 − -84969000 = -77368000 USD

-84969000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-162337000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Magenta Therapeutics, Inc. · 2025-12-31 Magenta Therapeutics, Inc. (edgar:1690585) Year-over-year change in Net income: -77368000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T14:33:14Z Snapshot: ec53128c25bf511416abc660a9fc93feb2bdc4739bc4672074c449d4cdcb5b7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1690585?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -162337000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm#3119082 Filing: 000169058526000006 Input fundies:NetIncome: -84969000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm#3120830 Filing: 000169058526000006
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 50.88 million

Prior period

−USD 78.18 million

2024-01-01 – 2024-12-31
Current period

−USD 129.06 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-129060000 − -78180000 = -50880000 USD

-78180000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-129060000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Magenta Therapeutics, Inc. · 2025-12-31 Magenta Therapeutics, Inc. (edgar:1690585) Year-over-year change in Operating cash flow: -50880000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T14:33:14Z Snapshot: ec53128c25bf511416abc660a9fc93feb2bdc4739bc4672074c449d4cdcb5b7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1690585?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -129060000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm#1774917 Filing: 000169058526000006 Input fundies:OperatingCashFlow: -78180000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm#1776773 Filing: 000169058526000006
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 2.04 million 100% of revenue
Operating costs Derived USD 179.97 million 8,839% of revenue
Operating income −USD 177.93 million −8,739% of revenue
Tax, interest and other Derived −USD 15.6 million −766% of revenue
Net income −USD 162.34 million −7,973% of revenue

Cash

Operating cash flow −USD 129.06 million −6,339% of revenue
Capital expenditure Unavailable An input is unavailable.
Free cash flow Derived Unavailable An input is unavailable.

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2016 Not shown: operating income or net income is not reported.
2017 Not shown: operating income or net income is not reported.
2018 Not shown: operating income or net income is not reported.
2019 Not shown: operating income or net income is not reported.
2023 Operating loss: operating costs were 1,805% of revenue.
2024 Operating loss: operating costs were 1,734% of revenue.
2025 Operating loss: operating costs were 8,839% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2016 2016-01-01 – 2016-12-31	0	9268000 Derived	-9268000	163000 Derived	-9431000	-6668000 Derived	Source 2016-01-01 – 2016-12-31: 0 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -9268000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -9431000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -6529000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 139000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	0	35727000 Derived	-35727000	-236000 Derived	-35491000	-24462000 Derived	Source 2017-01-01 – 2017-12-31: 0 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -35727000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -35491000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -22263000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 2199000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	0	59963000 Derived	-59963000	-2448000 Derived	-57515000	-49558000 Derived	Source 2018-01-01 – 2018-12-31: 0 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -59963000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -57515000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -41886000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 7672000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	0	82969000 Derived	-82969000	-6169000 Derived	-76800000	-60163000 Derived	Source 2019-01-01 – 2019-12-31: 0 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -82969000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -76800000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -57103000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 3060000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	2826000	51000000 Derived	-48174000	-4619000 Derived	-43555000	Unavailable	Source 2023-01-01 – 2023-12-31: 2826000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -48174000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -43555000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -36861000 USD Inspect Operating Cash Flow Open source
2024 2024-01-01 – 2024-12-31	6235000	108099000 Derived	-101864000	-16895000 Derived	-84969000	Unavailable	Source 2024-01-01 – 2024-12-31: 6235000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -101864000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -84969000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -78180000 USD Inspect Operating Cash Flow Open source
2025 2025-01-01 – 2025-12-31	2036000	179969000 Derived	-177933000	-15596000 Derived	-162337000	Unavailable	Source 2025-01-01 – 2025-12-31: 2036000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -177933000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -162337000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -129060000 USD Inspect Operating Cash Flow Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 2M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Revenue	0	Revenue: 0 Open source
20172017-12-31	Revenue	0	Revenue: 0 Open source
20182018-12-31	Revenue	0	Revenue: 0 Open source
20192019-12-31	Revenue	0	Revenue: 0 Open source
20232023-12-31	Revenue	2826000	Revenue: 2826000 Open source
20242024-12-31	Revenue	6235000	Revenue: 6235000 Open source
20252025-12-31	Revenue	2036000	Revenue: 2036000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-67.3% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Year over year	No prior comparable period	Revenue: 0 Open source
20172017-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20182018-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20192019-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20232023-12-31	Year over year	No prior comparable period	Revenue: 2826000 Open source
20242024-12-31	Year over year	120.6%	Revenue: 6235000 Open source Revenue: 2826000 Open source
20252025-12-31	Year over year	-67.3%	Revenue: 2036000 Open source Revenue: 6235000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -8,739.3% 2025

Net margin -7,973.3% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Operating margin	Not reported	Operating Income: -9268000 Open source Revenue: 0 Open source
20172017-12-31	Operating margin	Not reported	Operating Income: -35727000 Open source Revenue: 0 Open source
20182018-12-31	Operating margin	Not reported	Operating Income: -59963000 Open source Revenue: 0 Open source
20192019-12-31	Operating margin	Not reported	Operating Income: -82969000 Open source Revenue: 0 Open source
20232023-12-31	Operating margin	-1,704.7%	Operating Income: -48174000 Open source Revenue: 2826000 Open source
20242024-12-31	Operating margin	-1,633.7%	Operating Income: -101864000 Open source Revenue: 6235000 Open source
20252025-12-31	Operating margin	-8,739.3%	Operating Income: -177933000 Open source Revenue: 2036000 Open source
20162016-12-31	Net margin	Not reported	Net Income: -9431000 Open source Revenue: 0 Open source
20172017-12-31	Net margin	Not reported	Net Income: -35491000 Open source Revenue: 0 Open source
20182018-12-31	Net margin	Not reported	Net Income: -57515000 Open source Revenue: 0 Open source
20192019-12-31	Net margin	Not reported	Net Income: -76800000 Open source Revenue: 0 Open source
20232023-12-31	Net margin	-1,541.2%	Net Income: -43555000 Open source Revenue: 2826000 Open source
20242024-12-31	Net margin	-1,362.8%	Net Income: -84969000 Open source Revenue: 6235000 Open source
20252025-12-31	Net margin	-7,973.3%	Net Income: -162337000 Open source Revenue: 2036000 Open source
20162016-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -6529000 Open source Capital Expenditure: 139000 Open source
20172017-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -22263000 Open source Capital Expenditure: 2199000 Open source
20182018-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -41886000 Open source Capital Expenditure: 7672000 Open source
20192019-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -57103000 Open source Capital Expenditure: 3060000 Open source
20232023-12-31	Free cash flow margin	Not reported	Revenue: 2826000 Open source Operating Cash Flow: -36861000 Open source
20242024-12-31	Free cash flow margin	Not reported	Revenue: 6235000 Open source Operating Cash Flow: -78180000 Open source
20252025-12-31	Free cash flow margin	Not reported	Revenue: 2036000 Open source Operating Cash Flow: -129060000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -129.1M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Operating cash flow	-6529000	Operating Cash Flow: -6529000 Open source
20172017-12-31	Operating cash flow	-22263000	Operating Cash Flow: -22263000 Open source
20182018-12-31	Operating cash flow	-41886000	Operating Cash Flow: -41886000 Open source
20192019-12-31	Operating cash flow	-57103000	Operating Cash Flow: -57103000 Open source
20232023-12-31	Operating cash flow	-36861000	Operating Cash Flow: -36861000 Open source
20242024-12-31	Operating cash flow	-78180000	Operating Cash Flow: -78180000 Open source
20252025-12-31	Operating cash flow	-129060000	Operating Cash Flow: -129060000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -60.2M 2019

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Free cash flow	-6668000	Operating Cash Flow: -6529000 Open source Capital Expenditure: 139000 Open source
20172017-12-31	Free cash flow	-24462000	Operating Cash Flow: -22263000 Open source Capital Expenditure: 2199000 Open source
20182018-12-31	Free cash flow	-49558000	Operating Cash Flow: -41886000 Open source Capital Expenditure: 7672000 Open source
20192019-12-31	Free cash flow	-60163000	Operating Cash Flow: -57103000 Open source Capital Expenditure: 3060000 Open source
20232023-12-31	Free cash flow	Unavailable	Operating Cash Flow: -36861000 Open source
20242024-12-31	Free cash flow	Unavailable	Operating Cash Flow: -78180000 Open source
20252025-12-31	Free cash flow	Unavailable	Operating Cash Flow: -129060000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

7.1% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2016-12-31	Liabilities / assets	Not reported	No source recorded
20172017-12-31	Liabilities / assets	7.6%	Total Liabilities: 4142000 Open source Total Assets: 54463000 Open source
20182018-12-31	Liabilities / assets	7.4%	Total Liabilities: 11665000 Open source Total Assets: 157313000 Open source
20192019-12-31	Liabilities / assets	12.6%	Total Liabilities: 20321000 Open source Total Assets: 161514000 Open source
20232023-12-31	Liabilities / assets	5.9%	Total Liabilities: 10535000 Open source Total Assets: 179405000 Open source
20242024-12-31	Liabilities / assets	5.8%	Total Liabilities: 21531000 Open source Total Assets: 374008000 Open source
20252025-12-31	Liabilities / assets	7.1%	Total Liabilities: 37521000 Open source Total Assets: 530922000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

13.32× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2016-12-31	Current assets / current liabilities	Not reported	No source recorded
20172017-12-31	Current assets / current liabilities	12.68×	Current Assets: 52503000 Open source Current Liabilities: 4142000 Open source
20182018-12-31	Current assets / current liabilities	13.95×	Current Assets: 145321000 Open source Current Liabilities: 10419000 Open source
20192019-12-31	Current assets / current liabilities	10.62×	Current Assets: 149843000 Open source Current Liabilities: 14115000 Open source
20232023-12-31	Current assets / current liabilities	18.42×	Current Assets: 177451000 Open source Current Liabilities: 9631000 Open source
20242024-12-31	Current assets / current liabilities	15.22×	Current Assets: 280904000 Open source Current Liabilities: 18452000 Open source
20252025-12-31	Current assets / current liabilities	13.32×	Current Assets: 409438000 Open source Current Liabilities: 30732000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	−USD 9.43 million Exact value Exact value: -9431000 USD 2016-01-01 – 2016-12-31: -9431000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Magenta Therapeutics, Inc. · 2016-12-31 Magenta Therapeutics, Inc. (edgar:1690585) Net Income: -9431000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T14:33:14Z Snapshot: ec53128c25bf511416abc660a9fc93feb2bdc4739bc4672074c449d4cdcb5b7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1690585/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -9431000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1690585/000119312519125154/mgta-20181231.xml#777019 Filing: 000119312519125154 The citation records this snapshot. The page link may show a newer release later.	−USD 6.53 million Exact value Exact value: -6529000 USD 2016-01-01 – 2016-12-31: -6529000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Magenta Therapeutics, Inc. · 2016-12-31 Magenta Therapeutics, Inc. (edgar:1690585) Operating Cash Flow: -6529000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T14:33:14Z Snapshot: ec53128c25bf511416abc660a9fc93feb2bdc4739bc4672074c449d4cdcb5b7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1690585/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -6529000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1690585/000119312519125154/mgta-20181231.xml#776751 Filing: 000119312519125154 The citation records this snapshot. The page link may show a newer release later.	USD 139,000 Exact value Exact value: 139000 USD 2016-01-01 – 2016-12-31: 139000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Magenta Therapeutics, Inc. · 2016-12-31 Magenta Therapeutics, Inc. (edgar:1690585) Capital Expenditure: 139000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T14:33:14Z Snapshot: ec53128c25bf511416abc660a9fc93feb2bdc4739bc4672074c449d4cdcb5b7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1690585/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 139000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1690585/000119312519125154/mgta-20181231.xml#777883 Filing: 000119312519125154 The citation records this snapshot. The page link may show a newer release later.	−USD 6.67 million Calculation and evidence -6529000 − 139000 USD Exact free cash flow: -6668000 USD 2016-01-01 – 2016-12-31: -6529000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 139000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Magenta Therapeutics, Inc. · 2016-12-31 Magenta Therapeutics, Inc. (edgar:1690585) Free cash flow: -6668000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T14:33:14Z Snapshot: ec53128c25bf511416abc660a9fc93feb2bdc4739bc4672074c449d4cdcb5b7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1690585?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -6529000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1690585/000119312519125154/mgta-20181231.xml#776751 Filing: 000119312519125154 Input fundies:CapitalExpenditure: 139000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1690585/000119312519125154/mgta-20181231.xml#777883 Filing: 000119312519125154 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 35.49 million Exact value Exact value: -35491000 USD 2017-01-01 – 2017-12-31: -35491000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Magenta Therapeutics, Inc. · 2017-12-31 Magenta Therapeutics, Inc. (edgar:1690585) Net Income: -35491000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T14:33:14Z Snapshot: ec53128c25bf511416abc660a9fc93feb2bdc4739bc4672074c449d4cdcb5b7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1690585/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -35491000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1690585/000119312520059835/mgta-20191231.xml#129324 Filing: 000119312520059835 The citation records this snapshot. The page link may show a newer release later.	−USD 22.26 million Exact value Exact value: -22263000 USD 2017-01-01 – 2017-12-31: -22263000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Magenta Therapeutics, Inc. · 2017-12-31 Magenta Therapeutics, Inc. (edgar:1690585) Operating Cash Flow: -22263000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T14:33:14Z Snapshot: ec53128c25bf511416abc660a9fc93feb2bdc4739bc4672074c449d4cdcb5b7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1690585/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -22263000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1690585/000119312520059835/mgta-20191231.xml#113197 Filing: 000119312520059835 The citation records this snapshot. The page link may show a newer release later.	USD 2.2 million Exact value Exact value: 2199000 USD 2017-01-01 – 2017-12-31: 2199000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Magenta Therapeutics, Inc. · 2017-12-31 Magenta Therapeutics, Inc. (edgar:1690585) Capital Expenditure: 2199000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T14:33:14Z Snapshot: ec53128c25bf511416abc660a9fc93feb2bdc4739bc4672074c449d4cdcb5b7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1690585/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2199000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1690585/000119312520059835/mgta-20191231.xml#113403 Filing: 000119312520059835 The citation records this snapshot. The page link may show a newer release later.	−USD 24.46 million Calculation and evidence -22263000 − 2199000 USD Exact free cash flow: -24462000 USD 2017-01-01 – 2017-12-31: -22263000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 2199000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Magenta Therapeutics, Inc. · 2017-12-31 Magenta Therapeutics, Inc. (edgar:1690585) Free cash flow: -24462000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T14:33:14Z Snapshot: ec53128c25bf511416abc660a9fc93feb2bdc4739bc4672074c449d4cdcb5b7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1690585?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -22263000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1690585/000119312520059835/mgta-20191231.xml#113197 Filing: 000119312520059835 Input fundies:CapitalExpenditure: 2199000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1690585/000119312520059835/mgta-20191231.xml#113403 Filing: 000119312520059835 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 57.52 million Exact value Exact value: -57515000 USD 2018-01-01 – 2018-12-31: -57515000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Magenta Therapeutics, Inc. · 2018-12-31 Magenta Therapeutics, Inc. (edgar:1690585) Net Income: -57515000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T14:33:14Z Snapshot: ec53128c25bf511416abc660a9fc93feb2bdc4739bc4672074c449d4cdcb5b7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1690585/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -57515000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1690585/000119312520059835/mgta-20191231.xml#129176 Filing: 000119312520059835 The citation records this snapshot. The page link may show a newer release later.	−USD 41.89 million Exact value Exact value: -41886000 USD 2018-01-01 – 2018-12-31: -41886000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Magenta Therapeutics, Inc. · 2018-12-31 Magenta Therapeutics, Inc. (edgar:1690585) Operating Cash Flow: -41886000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T14:33:14Z Snapshot: ec53128c25bf511416abc660a9fc93feb2bdc4739bc4672074c449d4cdcb5b7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1690585/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -41886000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1690585/000119312520059835/mgta-20191231.xml#108236 Filing: 000119312520059835 The citation records this snapshot. The page link may show a newer release later.	USD 7.67 million Exact value Exact value: 7672000 USD 2018-01-01 – 2018-12-31: 7672000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Magenta Therapeutics, Inc. · 2018-12-31 Magenta Therapeutics, Inc. (edgar:1690585) Capital Expenditure: 7672000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T14:33:14Z Snapshot: ec53128c25bf511416abc660a9fc93feb2bdc4739bc4672074c449d4cdcb5b7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1690585/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 7672000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1690585/000119312520059835/mgta-20191231.xml#108646 Filing: 000119312520059835 The citation records this snapshot. The page link may show a newer release later.	−USD 49.56 million Calculation and evidence -41886000 − 7672000 USD Exact free cash flow: -49558000 USD 2018-01-01 – 2018-12-31: -41886000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 7672000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Magenta Therapeutics, Inc. · 2018-12-31 Magenta Therapeutics, Inc. (edgar:1690585) Free cash flow: -49558000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T14:33:14Z Snapshot: ec53128c25bf511416abc660a9fc93feb2bdc4739bc4672074c449d4cdcb5b7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1690585?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -41886000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1690585/000119312520059835/mgta-20191231.xml#108236 Filing: 000119312520059835 Input fundies:CapitalExpenditure: 7672000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1690585/000119312520059835/mgta-20191231.xml#108646 Filing: 000119312520059835 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 76.8 million Exact value Exact value: -76800000 USD 2019-01-01 – 2019-12-31: -76800000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Magenta Therapeutics, Inc. · 2019-12-31 Magenta Therapeutics, Inc. (edgar:1690585) Net Income: -76800000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T14:33:14Z Snapshot: ec53128c25bf511416abc660a9fc93feb2bdc4739bc4672074c449d4cdcb5b7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1690585/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -76800000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1690585/000119312521066707/d76599d10k.htm#1725630 Filing: 000119312521066707 The citation records this snapshot. The page link may show a newer release later.	−USD 57.1 million Exact value Exact value: -57103000 USD 2019-01-01 – 2019-12-31: -57103000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Magenta Therapeutics, Inc. · 2019-12-31 Magenta Therapeutics, Inc. (edgar:1690585) Operating Cash Flow: -57103000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T14:33:14Z Snapshot: ec53128c25bf511416abc660a9fc93feb2bdc4739bc4672074c449d4cdcb5b7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1690585/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -57103000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1690585/000119312521066707/d76599d10k.htm#1688103 Filing: 000119312521066707 The citation records this snapshot. The page link may show a newer release later.	USD 3.06 million Exact value Exact value: 3060000 USD 2019-01-01 – 2019-12-31: 3060000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Magenta Therapeutics, Inc. · 2019-12-31 Magenta Therapeutics, Inc. (edgar:1690585) Capital Expenditure: 3060000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T14:33:14Z Snapshot: ec53128c25bf511416abc660a9fc93feb2bdc4739bc4672074c449d4cdcb5b7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1690585/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3060000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1690585/000119312521066707/d76599d10k.htm#1691740 Filing: 000119312521066707 The citation records this snapshot. The page link may show a newer release later.	−USD 60.16 million Calculation and evidence -57103000 − 3060000 USD Exact free cash flow: -60163000 USD 2019-01-01 – 2019-12-31: -57103000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 3060000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Magenta Therapeutics, Inc. · 2019-12-31 Magenta Therapeutics, Inc. (edgar:1690585) Free cash flow: -60163000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T14:33:14Z Snapshot: ec53128c25bf511416abc660a9fc93feb2bdc4739bc4672074c449d4cdcb5b7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1690585?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -57103000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1690585/000119312521066707/d76599d10k.htm#1688103 Filing: 000119312521066707 Input fundies:CapitalExpenditure: 3060000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1690585/000119312521066707/d76599d10k.htm#1691740 Filing: 000119312521066707 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 74.9 million Exact value Exact value: -74900000 USD 2020-01-01 – 2020-12-31: -74900000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Magenta Therapeutics, Inc. · 2020-12-31 Magenta Therapeutics, Inc. (edgar:1690585) Net Income: -74900000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T14:33:14Z Snapshot: ec53128c25bf511416abc660a9fc93feb2bdc4739bc4672074c449d4cdcb5b7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1690585/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -74900000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1690585/000119312522068759/d237577d10k.htm#1622759 Filing: 000119312522068759 The citation records this snapshot. The page link may show a newer release later.	−USD 64.02 million Exact value Exact value: -64023000 USD 2020-01-01 – 2020-12-31: -64023000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Magenta Therapeutics, Inc. · 2020-12-31 Magenta Therapeutics, Inc. (edgar:1690585) Operating Cash Flow: -64023000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T14:33:14Z Snapshot: ec53128c25bf511416abc660a9fc93feb2bdc4739bc4672074c449d4cdcb5b7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1690585/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -64023000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1690585/000119312522068759/d237577d10k.htm#1588364 Filing: 000119312522068759 The citation records this snapshot. The page link may show a newer release later.	USD 400,000 Exact value Exact value: 400000 USD 2020-01-01 – 2020-12-31: 400000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Magenta Therapeutics, Inc. · 2020-12-31 Magenta Therapeutics, Inc. (edgar:1690585) Capital Expenditure: 400000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T14:33:14Z Snapshot: ec53128c25bf511416abc660a9fc93feb2bdc4739bc4672074c449d4cdcb5b7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1690585/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 400000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1690585/000119312522068759/d237577d10k.htm#1592193 Filing: 000119312522068759 The citation records this snapshot. The page link may show a newer release later.	−USD 64.42 million Calculation and evidence -64023000 − 400000 USD Exact free cash flow: -64423000 USD 2020-01-01 – 2020-12-31: -64023000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 400000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Magenta Therapeutics, Inc. · 2020-12-31 Magenta Therapeutics, Inc. (edgar:1690585) Free cash flow: -64423000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T14:33:14Z Snapshot: ec53128c25bf511416abc660a9fc93feb2bdc4739bc4672074c449d4cdcb5b7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1690585?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -64023000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1690585/000119312522068759/d237577d10k.htm#1588364 Filing: 000119312522068759 Input fundies:CapitalExpenditure: 400000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1690585/000119312522068759/d237577d10k.htm#1592193 Filing: 000119312522068759 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 71.1 million Exact value Exact value: -71100000 USD 2021-01-01 – 2021-12-31: -71100000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Magenta Therapeutics, Inc. · 2021-12-31 Magenta Therapeutics, Inc. (edgar:1690585) Net Income: -71100000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T14:33:14Z Snapshot: ec53128c25bf511416abc660a9fc93feb2bdc4739bc4672074c449d4cdcb5b7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1690585/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -71100000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1690585/000119312523144240/d483652ds4.htm#3848573 Filing: 000119312523144240 The citation records this snapshot. The page link may show a newer release later.	−USD 59.53 million Exact value Exact value: -59531000 USD 2021-01-01 – 2021-12-31: -59531000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Magenta Therapeutics, Inc. · 2021-12-31 Magenta Therapeutics, Inc. (edgar:1690585) Operating Cash Flow: -59531000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T14:33:14Z Snapshot: ec53128c25bf511416abc660a9fc93feb2bdc4739bc4672074c449d4cdcb5b7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1690585/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -59531000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1690585/000119312523144240/d483652ds4.htm#3815729 Filing: 000119312523144240 The citation records this snapshot. The page link may show a newer release later.	USD 1.26 million Exact value Exact value: 1264000 USD 2021-01-01 – 2021-12-31: 1264000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Magenta Therapeutics, Inc. · 2021-12-31 Magenta Therapeutics, Inc. (edgar:1690585) Capital Expenditure: 1264000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T14:33:14Z Snapshot: ec53128c25bf511416abc660a9fc93feb2bdc4739bc4672074c449d4cdcb5b7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1690585/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1264000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1690585/000119312523144240/d483652ds4.htm#3818626 Filing: 000119312523144240 The citation records this snapshot. The page link may show a newer release later.	−USD 60.8 million Calculation and evidence -59531000 − 1264000 USD Exact free cash flow: -60795000 USD 2021-01-01 – 2021-12-31: -59531000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 1264000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Magenta Therapeutics, Inc. · 2021-12-31 Magenta Therapeutics, Inc. (edgar:1690585) Free cash flow: -60795000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T14:33:14Z Snapshot: ec53128c25bf511416abc660a9fc93feb2bdc4739bc4672074c449d4cdcb5b7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1690585?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -59531000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1690585/000119312523144240/d483652ds4.htm#3815729 Filing: 000119312523144240 Input fundies:CapitalExpenditure: 1264000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1690585/000119312523144240/d483652ds4.htm#3818626 Filing: 000119312523144240 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 28.48 million Exact value Exact value: -28476000 USD 2022-01-01 – 2022-12-31: -28476000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Magenta Therapeutics, Inc. · 2022-12-31 Magenta Therapeutics, Inc. (edgar:1690585) Net Income: -28476000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:33:14Z Snapshot: ec53128c25bf511416abc660a9fc93feb2bdc4739bc4672074c449d4cdcb5b7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1690585/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -28476000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1690585/000095017024034681/dnth-20231231.htm#2285207 Filing: 000095017024034681 The citation records this snapshot. The page link may show a newer release later.	−USD 29.07 million Exact value Exact value: -29070000 USD 2022-01-01 – 2022-12-31: -29070000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Magenta Therapeutics, Inc. · 2022-12-31 Magenta Therapeutics, Inc. (edgar:1690585) Operating Cash Flow: -29070000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:33:14Z Snapshot: ec53128c25bf511416abc660a9fc93feb2bdc4739bc4672074c449d4cdcb5b7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1690585/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -29070000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1690585/000095017024034681/dnth-20231231.htm#1500518 Filing: 000095017024034681 The citation records this snapshot. The page link may show a newer release later.	USD 314,000 Exact value Exact value: 314000 USD 2022-01-01 – 2022-12-31: 314000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Magenta Therapeutics, Inc. · 2022-12-31 Magenta Therapeutics, Inc. (edgar:1690585) Capital Expenditure: 314000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:33:14Z Snapshot: ec53128c25bf511416abc660a9fc93feb2bdc4739bc4672074c449d4cdcb5b7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1690585/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 314000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1690585/000119312523144240/d483652ds4.htm#3818168 Filing: 000119312523144240 The citation records this snapshot. The page link may show a newer release later.	−USD 29.38 million Calculation and evidence -29070000 − 314000 USD Exact free cash flow: -29384000 USD 2022-01-01 – 2022-12-31: -29070000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 314000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Magenta Therapeutics, Inc. · 2022-12-31 Magenta Therapeutics, Inc. (edgar:1690585) Free cash flow: -29384000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:33:14Z Snapshot: ec53128c25bf511416abc660a9fc93feb2bdc4739bc4672074c449d4cdcb5b7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1690585?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -29070000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1690585/000095017024034681/dnth-20231231.htm#1500518 Filing: 000095017024034681 Input fundies:CapitalExpenditure: 314000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1690585/000119312523144240/d483652ds4.htm#3818168 Filing: 000119312523144240 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 43.56 million Exact value Exact value: -43555000 USD 2023-01-01 – 2023-12-31: -43555000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Magenta Therapeutics, Inc. · 2023-12-31 Magenta Therapeutics, Inc. (edgar:1690585) Net Income: -43555000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T14:33:14Z Snapshot: ec53128c25bf511416abc660a9fc93feb2bdc4739bc4672074c449d4cdcb5b7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1690585/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -43555000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1690585/000095017025037131/dnth-20241231.htm#2907709 Filing: 000095017025037131 The citation records this snapshot. The page link may show a newer release later.	−USD 36.86 million Exact value Exact value: -36861000 USD 2023-01-01 – 2023-12-31: -36861000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Magenta Therapeutics, Inc. · 2023-12-31 Magenta Therapeutics, Inc. (edgar:1690585) Operating Cash Flow: -36861000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T14:33:14Z Snapshot: ec53128c25bf511416abc660a9fc93feb2bdc4739bc4672074c449d4cdcb5b7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1690585/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -36861000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1690585/000095017025037131/dnth-20241231.htm#1742797 Filing: 000095017025037131 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2024 2024-01-01 – 2024-12-31	−USD 84.97 million Exact value Exact value: -84969000 USD 2024-01-01 – 2024-12-31: -84969000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Magenta Therapeutics, Inc. · 2024-12-31 Magenta Therapeutics, Inc. (edgar:1690585) Net Income: -84969000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T14:33:14Z Snapshot: ec53128c25bf511416abc660a9fc93feb2bdc4739bc4672074c449d4cdcb5b7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1690585/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -84969000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm#3120830 Filing: 000169058526000006 The citation records this snapshot. The page link may show a newer release later.	−USD 78.18 million Exact value Exact value: -78180000 USD 2024-01-01 – 2024-12-31: -78180000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Magenta Therapeutics, Inc. · 2024-12-31 Magenta Therapeutics, Inc. (edgar:1690585) Operating Cash Flow: -78180000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T14:33:14Z Snapshot: ec53128c25bf511416abc660a9fc93feb2bdc4739bc4672074c449d4cdcb5b7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1690585/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -78180000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm#1776773 Filing: 000169058526000006 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2025 2025-01-01 – 2025-12-31	−USD 162.34 million Exact value Exact value: -162337000 USD 2025-01-01 – 2025-12-31: -162337000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Magenta Therapeutics, Inc. · 2025-12-31 Magenta Therapeutics, Inc. (edgar:1690585) Net Income: -162337000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T14:33:14Z Snapshot: ec53128c25bf511416abc660a9fc93feb2bdc4739bc4672074c449d4cdcb5b7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1690585/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -162337000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm#3119082 Filing: 000169058526000006 The citation records this snapshot. The page link may show a newer release later.	−USD 129.06 million Exact value Exact value: -129060000 USD 2025-01-01 – 2025-12-31: -129060000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Magenta Therapeutics, Inc. · 2025-12-31 Magenta Therapeutics, Inc. (edgar:1690585) Operating Cash Flow: -129060000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T14:33:14Z Snapshot: ec53128c25bf511416abc660a9fc93feb2bdc4739bc4672074c449d4cdcb5b7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1690585/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -129060000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm#1774917 Filing: 000169058526000006 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

61 filings · 2,046 latest values · 2,046 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001690585, 1690585, DNTH, MGTA, edgar:1690585

Also known as DIANTHUS THERAPEUTICS, INC., Dianthus Therapeutics, Inc., Dianthus Therapeutics, Inc. /DE/, MAGENTA THERAPEUTICS, INC., Magenta Therapeutics, Inc, Magenta Therapeutics, Inc.

Magenta Therapeutics, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation